Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced nsclc—real world efficacy
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced nsclc—real world efficacy. / Mouritzen, Mette T.; Carus, Andreas; Ladekarl, Morten; Meldgaard, Peter; Nielsen, Anders W.M.; Livbjerg, Anna; Larsen, Jacob W.; Skuladottir, Halla; Kristiansen, Charlotte; Wedervang, Kim; Schytte, Tine; Hansen, Karin H.; Østby, Anne Cathrine; Frank, Malene S.; Lauritsen, Jakob; Sørensen, Jens B.; Langer, Seppo W.; Persson, Gitte F.; Andersen, Jon L.; Frary, Johanna M.C.; Drivsholm, Lars B.; Vesteghem, Charles; Christensen, Heidi S.; Bjørnhart, Birgitte; Pøhl, Mette.
In: Cancers, Vol. 13, No. 19, 4846, 2021.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced nsclc—real world efficacy
AU - Mouritzen, Mette T.
AU - Carus, Andreas
AU - Ladekarl, Morten
AU - Meldgaard, Peter
AU - Nielsen, Anders W.M.
AU - Livbjerg, Anna
AU - Larsen, Jacob W.
AU - Skuladottir, Halla
AU - Kristiansen, Charlotte
AU - Wedervang, Kim
AU - Schytte, Tine
AU - Hansen, Karin H.
AU - Østby, Anne Cathrine
AU - Frank, Malene S.
AU - Lauritsen, Jakob
AU - Sørensen, Jens B.
AU - Langer, Seppo W.
AU - Persson, Gitte F.
AU - Andersen, Jon L.
AU - Frary, Johanna M.C.
AU - Drivsholm, Lars B.
AU - Vesteghem, Charles
AU - Christensen, Heidi S.
AU - Bjørnhart, Birgitte
AU - Pøhl, Mette
N1 - Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021
Y1 - 2021
N2 - Background The selection of patients with non-small cell lung cancer (NSCLC) for immune checkpoint inhibitor (ICI) treatment remains challenging. This real-world study aimed to compare the overall survival (OS) before and after the implementation of ICIs, to identify OS prognostic factors, and to assess treatment data in first-line (1L) ICI-treated patients without epidermal growth factor receptor mutation or anaplastic lymphoma kinase translocation. Methods Data from the Danish NSCLC population initiated with 1L palliative antineoplastic treatment from 1 January 2013 to 1 October 2018, were extracted from the Danish Lung Cancer Registry (DLCR). Long-term survival and median OS pre-and post-approval of 1L ICI were compared. From electronic health records, additional clinical and treatment data were obtained for ICI-treated patients from 1 March 2017 to 1 October 2018. Results The OS was significantly improved in the DLCR post-approval cohort (n = 2055) compared to the pre-approval cohort (n = 1658). The 3-year OS rates were 18% (95% CI 15.6–20.0) and 6% (95% CI 5.1–7.4), respectively. On multivariable Cox regression, bone (HR = 1.63) and liver metastases (HR = 1.47), performance status (PS) 1 (HR = 1.86), and PS ≥ 2 (HR = 2.19) were significantly associated with poor OS in ICI-treated patients. Conclusion OS significantly improved in patients with advanced NSCLC after ICI implementation in Denmark. In ICI-treated patients, PS ≥ 1, and bone and liver metastases were associated with a worse prognosis.
AB - Background The selection of patients with non-small cell lung cancer (NSCLC) for immune checkpoint inhibitor (ICI) treatment remains challenging. This real-world study aimed to compare the overall survival (OS) before and after the implementation of ICIs, to identify OS prognostic factors, and to assess treatment data in first-line (1L) ICI-treated patients without epidermal growth factor receptor mutation or anaplastic lymphoma kinase translocation. Methods Data from the Danish NSCLC population initiated with 1L palliative antineoplastic treatment from 1 January 2013 to 1 October 2018, were extracted from the Danish Lung Cancer Registry (DLCR). Long-term survival and median OS pre-and post-approval of 1L ICI were compared. From electronic health records, additional clinical and treatment data were obtained for ICI-treated patients from 1 March 2017 to 1 October 2018. Results The OS was significantly improved in the DLCR post-approval cohort (n = 2055) compared to the pre-approval cohort (n = 1658). The 3-year OS rates were 18% (95% CI 15.6–20.0) and 6% (95% CI 5.1–7.4), respectively. On multivariable Cox regression, bone (HR = 1.63) and liver metastases (HR = 1.47), performance status (PS) 1 (HR = 1.86), and PS ≥ 2 (HR = 2.19) were significantly associated with poor OS in ICI-treated patients. Conclusion OS significantly improved in patients with advanced NSCLC after ICI implementation in Denmark. In ICI-treated patients, PS ≥ 1, and bone and liver metastases were associated with a worse prognosis.
KW - Advanced lung cancer
KW - Anti-PD-1
KW - Cancer immunotherapy
KW - Clinical prognostic factors
KW - Danish registry
KW - First-line treatment
KW - Immune checkpoint inhibitors
KW - Non-small cell lung cancer
KW - Overall survival
KW - Real-world evidence
U2 - 10.3390/cancers13194846
DO - 10.3390/cancers13194846
M3 - Journal article
C2 - 34638329
AN - SCOPUS:85115874983
VL - 13
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 19
M1 - 4846
ER -
ID: 281161582